Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate
NCT04059874
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
donafenib tablets
Sponsor
First Affiliated Hospital of Zhejiang University